Understanding immune-related adverse events in cancer treatment
Official title: Immune cell states in endocrine immune related adverse events (IRAEs)
Funded at University of California Los Angeles · NIH-10845211 · Data updated 2026-11-12
This study is looking at how certain immune-related side effects can happen quickly in cancer patients receiving special treatments, and by tracking changes in specific immune cells, it hopes to find ways to better manage or prevent these side effects for future patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | September 10, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $218,096 |
| NIH project number | 1U19AI181729-01 |
| Project ID | NIH-10845211 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients undergoing immune checkpoint inhibitor therapy who may develop or are experiencing immune-related adverse events.
✕Less likely to help
Patients who are not receiving immune checkpoint inhibitors or do not have autoimmune responses may not benefit from this research.
What this research studies
This research investigates immune-related adverse events (IRAEs), which are autoimmune diseases that can occur in patients receiving immune checkpoint inhibitor therapy for cancer. The study aims to understand how these adverse events rapidly progress by examining changes in specific immune cells, particularly Tcf1+ progenitor T cells, in patients over time. By identifying the mechanisms driving these autoimmune responses, the research seeks to uncover potential therapeutic targets that could help manage or prevent IRAEs. Patients participating in this research may contribute to a better understanding of how to mitigate these adverse effects.
Why it matters
Potential benefit: If successful, this research could lead to improved management strategies for patients experiencing autoimmune complications from cancer therapies.
How similar studies have gone: Previous research has shown promising results in understanding autoimmune responses related to cancer therapies, indicating that this approach may yield valuable insights.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Lechner, Melissa G — University of California Los Angeles
- Study coordinator: Lechner, Melissa G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.